$VALN News

Valneva SE (VALN) Q1 2026 Earnings Call Transcript

Transcript: Valneva Q1 2026 Earnings Conference Call

Valneva Lowers FY2026 Sales Guidance from $180.443M-$197.906M to $169.795M-$187.360M vs $192.800M Est

Valneva Q1 EPS $(0.42) Misses $(0.21) Estimate, Sales $36.189M Miss $46.270M Estimate

Valneva Announces the Successful Completion of an €84 million Reserved Offering

Guggenheim Cuts PT on Valneva SE (VALN) to $11 From $13

Declaration of shares and voting rights of Valneva SE – March 2026

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Valneva shares are trading lower after the company announced with Pfizer topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial. The vaccine candidate PF-07307405 demonstrated efficacy of more than 70% in preventing Lyme disease in individuals aged five years and above.

Valneva shares are trading lower after the company announced with Pfizer topline results from the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial. The vaccine candidate PF-07307405 demonstrated efficacy of more than 70% in preventing Lyme disease in individuals aged five years and above.

Valneva SE 2025 Q4 - Results - Earnings Call Presentation

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Valneva Affirms FY2026 Sales Guidance of $180.443M-$197.906M

Valneva Q4 EPS $(0.68) Misses $(0.21) Estimate, Sales $55.516M Miss $56.190M Estimate

Valneva Posts €174.7M In Preliminary 2025 Revenues, Up From €169.6M In 2024, With €109.7M Cash; Guides 2026 Total Revenues Of €155M-€170M, Product Sales €145M-€160M, With Phase 3 Lyme Disease Data Expected In H1 2026

Valneva Announces U.K.'s Commission On Human Medicines Restricts People Aged 60+ From Using IXCHIQ Chikungunya Vaccine

Valneva And Instituto Butantan Partner To Deploy IXCHIQ Vaccine In Brazil's Pilot Program, Focusing On Large-Scale Coverage To Address Chikungunya's Growing Public Health Threat

Valneva Steps Back From US Approval Bid For Chikungunya Vaccine

Reported Monday, Valneva Withdraws IXCHIQ Chikungunya Vaccine BLA And IND In The US Following FDA Suspension And New Serious Adverse Event Review